Faecal fat average 1 9 g daily. Serum calcium 9 4, phosphate 3-1 mg/100 ml. Serum antibodies (Dr Deborah Doniach) were as shown in Table 1 . It has not been possible to demonstrate adrenal auto-antibodies in the patient. Treatment and progress: Improved on cortisone acetate 12-5 mg t.d.s. with later addition of fludrocortisone 0 1 mg daily. Two years later became less well again, lacking in energy, short of breath; improved on-thyroxine but noted to be losing weight and complained of 'sticky' urine and infections of toes. Glycosuria 2%. Glucose tolerance: fasting blood sugar 200 mg/100 ml; 390 mg/100 ml at one hour; 350 mg/100 ml at two hours. Diabetes not controlled by chlorpropamide 500 mg and phenformin 100 mg daily. Now receiving 40 units insulin lente daily. Also receiving thyroxine 0'2 mg daily and vitamin B12 100 pg monthly.
Comment
The association of Addison's disease and primary hypothyroidism (Schmidt's syndrome) is well known and diabetes mellitus has been reported in some cases (Carpenter et al. 1964) . The occurrence of addisonian anemia in addition to these three is unusual, although the former is commonly associated with primary hypothyroidism alone. It is tempting to regard these multiple deficiencies in this patient as autoimmune disturbances having a familial incidence. Anamia essentially normocytic -and normochromic, failing to respond to full hWmatinic therapy. Hb 52 %, reticulocytes 1 %, WBC 2,000-5,000, platelets 125,000-200,000/c.mm later falling to 30,000-90,000/c.mm. Serum bilirubin 0 7 mg/100 ml. Coombs' test negative. Marrow showed depressed erythropoiesis. Spleen, at first two fingerbreadths below costal margin, became impalpable after two months. Treated with blood transfusion whenever hvmoglobin fell below 35%; in all received 49 pints in twelve months. Methylprednisolone 4 mg t.d.s. may have reduced rate of blood loss. Eventually radioactive chromium labelled red cell studies revealed a mean red cell survival time of 30 days (normal 120 days) and a concentration of radioactivity over the spleen.
Splenectomy
July 1961 (Mr K A Moore): Spleen enlarged to twice normal. Histology revealed no significant abnormality.
Operation was followed by return of all blood elements to normal, and these have remained so without any supportive therapy other than oral iron. It was suggested that all these disorders might be manifestations of disturbed auto-antibody processes. Investigations: Urine 17-OS 7 mg/24 hours. The excretion of gonadotrophin was 30 mg International Reference Preparation Human Menopausal Gonadotrophin (IRP-HMG)/24 hours by uterine weight assay (i.e. upper normal level).
Eunuchoid Treated with Gonadotrophins
Buccal smears showed no Barr bodies. Testicular biopsy showed small seminiferous tubules with spermatogonia but there was no evidence of spermatogenesis or Leydig cells. Skull X-ray and tests of pituitary, thyroid and adrenal cortex function gave normal results.
Treatment: Injections of human pituitary Follicle Stimulating Hormone (FSH), each injection equivalent to 600 mg IRP-HMG, were given three times a week from April to August 1964, causing increase in testicular size, with enlargement of tubules. FSH injections, each equivalent to 2,000 mg IRP-HMG, from August to October produced a further increase in testicular size. No Leydig cells could be seen in biopsies taken in August and October. Human chorionic gonadotrophin (HCG) 12,000 units, was added to each injection of FSH from October 1964 to February 1965. During this period 17-OS excretion rose to 25 mg/24 hours and finally to 66 mg; the excretion of cestriol was 25 Ig/24 hours, rising to 49 ,ug; body weight increased 13 kg; muscular development was evident and facial hair increased. The testes now measure 30 x 20 mm. The first nocturnal emission occurred after three injections of both hormones. Testicular biopsy in February showed a few spermatozoa lying in dilated tubules and nests of Leydig cells were prominent. In March spermatozoa appeared in ejaculates, the count being one million per ml.
The following case was also shown:
Islet Cell Carcinoma of the Pancreas Dr J R Hearnshaw (for Dr J D N Nabarro)
